Parent‐Reported Medication Side‐Effects and Their Impact on Health‐Related Quality of Life in Children with Juvenile Idiopathic Arthritis

2021 ◽  
Author(s):  
Gaëlle Chédeville ◽  
Katherine McGuire ◽  
David A. Cabral ◽  
Natalie J. Shiff ◽  
Dax G. Rumsey ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Juvenile Idiopathic Arthritis ◽  
Side Effects ◽  
Health Related Quality ◽  
Medication Side Effects ◽  
Medication Side ◽  
Related Quality ◽  
Health Related

scholarly journals Predictors of health-related quality of life in children and adolescents with juvenile idiopathic arthritis: Results from a web-based survey

2012 ◽  
Vol 64 (5) ◽  
pp. 694-703 ◽  
Author(s):  
L. Haverman ◽  
M. A. Grootenhuis ◽  
J. M. van den Berg ◽  
M. van Veenendaal ◽  
K. M. Dolman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Juvenile Idiopathic Arthritis ◽  
Children And Adolescents ◽  
Health Related Quality ◽  
Web Based ◽  
Related Quality ◽  
Health Related

scholarly journals Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study

Rheumatology ◽  
2006 ◽  
Vol 46 (2) ◽  
pp. 314-320 ◽  
Author(s):  
R. Gutierrez-Suarez ◽  
A. Pistorio ◽  
A. Cespedes Cruz ◽  
X. Norambuena ◽  
B. Flato ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cohort Study ◽  
Juvenile Idiopathic Arthritis ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

CLO19-050: Risk of Health- Related Quality of Life (HRQOL) Events in Patients With Advanced Solid Tumors Treated With Cabozantinib: A Combined Analysis of Four Phase 3 Randomized Controlled Trials

2019 ◽  
Vol 17 (3.5) ◽  
pp. CLO19-050
Author(s):  
Sriman Swarup ◽  
Anita Sultan ◽  
Nusrat Jahan ◽  
Upama Sharma ◽  
Nimesh Adhikari ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Solid Tumors ◽  
Meta Analysis ◽  
Health Related Quality ◽  
Phase 3 ◽  
Randomized Controlled ◽  
Related Quality ◽  
Health Related

Background: VEGFR, KIT, RET, and MET pathways are implicated in several solid tumors. Cabozantinib is an oral inhibitor of these kinase pathways, and hence has found its use in treatment of multiple malignancies. However, it has several side effects that can limit tolerance amongst patients. We performed a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the risk of health-related quality of life (HRQOL) events in patients with advanced solid tumors treated with cabozantinib. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases, and meeting abstracts through September 30, 2018. Phase 3 trials that mention HRQOL events like pain, arthralgia, fatigue, and reduced appetite as adverse effects were incorporated in the analysis. Mantel-Haenszel method was used to calculate the estimated pooled risk ratio (RR) with 95% CI. Random effects model was applied. Results: 4 phase 3 RCTs with a total of 2,703 patients with medullary thyroid cancer, prostate cancer, renal cell carcinoma, and hepatocellular carcinoma were eligible. Studies comparing cabozantinib (C) vs everolimus, C vs placebo, C vs prednisone were included in the analysis. The relative risks of all-grade side effects were as follows: fatigue, 1.378 (95% CI: 1.236–1.536; P<.0001); asthenia, 1.704 (95% CI: 1.190–2.441; P=.004); reduced appetite, 2.088 (95% CI: 1.471–2.964; P<.0001); back pain, 1.047 (95% CI: 0.871–1.259; P=.626); pain in limbs, 1.444 (95% CI: 1.128–1.847; P=.004); arthralgia, 0.982 (95% CI: 0.707–1.363; P=.912). The RR of high-grade side effects were as follows: fatigue, 1.937 (95% CI: 1.483–2.528; P<.0001); asthenia, 2.211 (95% CI: 1.536–3.184; P<.0001); reduced appetite, 4.329 (95% CI: 2.372–7.900; P<.0001); back pain, 1.227 (95% CI: 0.738–2.040; P=.431); pain in limbs, 2.933 (95% CI: 1.127–7.635; P=.028); arthralgia, 0.820 (95% CI: 0.394–1.709; P=.597). Conclusion: Our meta-analysis showed that cabozantinib contributed to significant toxicity of all grades of fatigue, asthenia, pain in limbs, and reduced appetite. Identifying and addressing these toxicities will be important in improving quality of life for these patients.

Risk of health-related quality-of-life events and pulmonary toxicities in patients with cancer treated with poly adenosine diphosphate ribose polymerase inhibitors: A meta-analysis of seven phase III trials.

2018 ◽  
Vol 36 (34_suppl) ◽  
pp. 213-213
Author(s):  
Sriman Swarup ◽  
Anita Sultan ◽  
Myo Zaw ◽  
Rachana Yendala ◽  
Myat M. Han ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Meta Analysis ◽  
Adenosine Diphosphate ◽  
Parp Inhibitors ◽  
Phase Iii ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

213 Background: Poly adenosine diphosphate ribose polymerase (PARP) enzymes aide in the repair of DNA damage. PARP inhibitors showed synthetic lethality in cancer cells and were utilized in many solid tumors with notable toxicities. Fatigue and pain are the major determinants of health-related quality of life (HRQOL) in cancer patients undergoing chemotherapy. We undertook a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the risk of HRQOL events and pulmonary toxicities. Methods: MEDLINE, EMBASE databases and meeting abstracts from inception through June 2018 were queried. Phase III RCTs that mention HRQOL events and pulmonary toxicities as adverse effects were included. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Random effects model was applied. Results: 3188 patients from 7 phase III RCTs with breast, ovarian, and gastric cancer were eligible. Studies compared olaparib or niraparib or rucaparib versus placebo, olaparib vs single agent chemotherapy, iniparib + gemcitabine / carboplatin (GC) versus GC, veliparib + C versus C and olaparib + paclitaxel versus paclitaxel. The RR of all-grade side effects were as follows: fatigue, 1.26 (95% CI: 1.07 – 1.49, P = 0.006); decreased appetite, 1.42 (95% CI: 1.18 – 1.71, P < 0.001); arthralgia, 1.05 (95% CI: 0.83 – 1.34, P = 0.65); headache, 1.35 (95% CI: 0.99 – 1.84, P = 0.05); cough, 1.75 (95% CI: 1.17 – 2.62, P = 0.006); dyspnea, 1.40 (95% CI: 0.90 – 2.18, P = 0.12); and upper respiratory infections, 1.70 (95% CI: 0.97 – 3.00, P = 0.06). The RR of high-grade side effects were as follows: fatigue, 1.94 (95% CI: 1.24 – 3.04, P = 0.004); arthralgia, 1.37 (95% CI: 0.29 – 6.51, P = 0.68); headache, 1.09 (95% CI: 0.47 – 2.55, P = 0.83); and dyspnea, 1.02 (95% CI: 0.44 – 2.36, P = 0.95). Conclusions: The risk of developing all grades of fatigue as well as any-grade cough and decreased appetite was high in PARP inhibitors group, compared to control arm. Recognizing these toxicities and providing good supportive care is vital in enhancing patients’ quality of life.

scholarly journals A new short and simple health-related quality of life measurement for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis

Rheumatology ◽  
2010 ◽  
Vol 49 (7) ◽  
pp. 1272-1280 ◽  
Author(s):  
Giovanni Filocamo ◽  
Benedetta Schiappapietra ◽  
Marta Bertamino ◽  
Angela Pistorio ◽  
Nicolino Ruperto ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Juvenile Idiopathic Arthritis ◽  
Health Related Quality ◽  
Initial Validation ◽  
Life Measurement ◽  
Related Quality ◽  
Health Related ◽  
Paediatric Rheumatic Diseases ◽  
Quality Of Life Measurement
Sign in / Sign up

Export Citation Format

Share Document